81.1%).OS was not significantly different in patients treated with letrozole (HR, 0.91; 95% CI, 0.75–1.11;P= .35).
DFS was significantly superior in patients treated with letrozole (HR, 0.82; 95% CI, 0.71–0.95;P= .007; 5-year DFS, 84.0% vs.
81.1%).
OS was not significantly different in patients treated with letrozole (HR, 0.91; 95% CI, 0.75–1.11;P= .35).
In a meta-analysis, which included 9,885 women from multiple trials, the 10-year recurrence risk was 19.1% in the AI group versus 22.7% in the tamoxifen group (RR, 0.80; 95% CI, 0.73–0.88;P< .001).
The overall 10-year mortality rate was also reduced from 24.0% to 21.3%.